Skip to Content

Notice

Notice of Availability of Environmental Assessment and Finding of No Significant Impact for License Amendment for Message Pharmaceuticals, Inc.'s Facility in Malvern, PA

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Nuclear Regulatory Commission.

ACTION:

Notice of Availability of Environmental Assessment and Finding of No Significant Impact.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Sattar Lodhi, Nuclear Materials Safety Branch 2, Division of Nuclear Materials Safety, Region I, 475 Allendale Road, King of Prussia, Pennsylvania, 19406, telephone (610) 337-5364 fax (610) 337-5269; or by e-mail: asl@nrc.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Introduction

The Nuclear Regulatory Commission (NRC) is considering the issuance of a license amendment to Message Pharmaceuticals, Inc.'s Materials License No. 37-30462-01, to authorize release of its facility in Malvern, Pennsylvania for unrestricted use. NRC has prepared an Environmental Assessment (EA) in support of this action in accordance with the requirements of 10 CFR part 51. Based on the EA, the NRC has concluded that a Finding of No Significant Impact (FONSI) is appropriate. The amendment will be issued following the publication of this Notice.

II. EA Summary

The purpose of the proposed action is to authorize the release of the licensee's Malvern, Pennsylvania facility for unrestricted use. Message Pharmaceuticals, Inc., was authorized by NRC from July 29, 1998, to use radioactive materials for research and development purposes at the site. On January 5, 2004, Message Pharmaceuticals, Inc., requested that NRC release the facility for unrestricted use. Message Pharmaceuticals, Inc., has conducted surveys of the facility and determined that the facility meets the license termination criteria in Subpart E of 10 CFR part 20. The NRC staff has prepared an EA in support of the proposed license amendment.

III. Finding of No Significant Impact

The staff has prepared the EA (summarized above) in support of the proposed license amendment to terminate the license and release the facility for unrestricted use. The NRC staff has evaluated Message Pharmaceuticals, Inc.'s request and the results of the surveys and has concluded that the completed action complies with the criteria in Subpart E of 10 CFR part 20. The staff has found that the environmental impacts from the proposed action are bounded by the impacts evaluated by the “Generic Environmental Impact Statement in Support of Rulemaking on Radiological Criteria for License Termination of NRC-Licensed Facilities” (NUREG-1496). On the basis of the EA, the NRC has concluded that the environmental impacts from the proposed action are expected to be insignificant and has determined not to prepare an environmental impact statement for the proposed action.

IV. Further Information

The EA and the documents related to this proposed action, including the application for the license amendment and supporting documentation, are available for inspection at NRC's Public Electronic Reading Room at http://www.nrc.gov/​reading-rm/​adams.html (ADAMS Accession Nos. ML040250011 and ML041040862). These documents are also available for inspection and copying for a fee at the Region I Office, 475 Allendale Road, King of Prussia, Pennsylvania, 19406. Persons who do not have access to ADAMS, should contact the NRC PDR Reference staff by telephone at 1-800-397-4209 or (301) 415-4737, of by e-mail to pdr@nrc.gov.

Start Signature

For the Nuclear Regulatory Commission.

Dated at King of Prussia, Pennsylvania this 18th day of May, 2004.

John D. Kinneman,

Chief, Nuclear Materials Safety Branch 2, Division of Nuclear Materials Safety Region I

End Signature. End Supplemental Information

[FR Doc. 04-11758 Filed 5-24-04; 8:45 am]

BILLING CODE 7590-01-P